Lilly's 2012 earnings forecast misses analyst estimates

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast that missed analyst estimates by a wide margin, sending shares down in early trading.

Full-year profit will be $3.10 to $3.20 a share, less than the average estimate of $3.67 by 19 analysts surveyed by Bloomberg. Annual revenue is expected to be between $21.8 billion and $22.8 billion, the company said in a statement.

The company's 2012 prediction would mean a drop of between 26 percent and 28 percent from its forecast for earnings of $4.30 to $4.35 per share in 2011.

Lilly shares fell more than 3 percent, to $39.34 each, early Thursday morning before rising in the afternoon. Shares closed at $40.30, down 1 percent on the day.

Lilly said 2011 earnings, excluding some items, met or exceeded its forecast of $4.30 to $4.35 a share. The drugmaker is investing in research, seeking to overcome the loss of patents on its best-selling medication Zyprexa, with revenue of $5 billion in 2010, and other medicines, without a major merger.

“The guidance came in well below expectations,” said Seamus Fernandez, an analyst for Leerink Swann & Co. “The patent loss of Zyprexa means revenue is coming down faster than people expected.”

Unlike other drug companies, Lilly is continuing to spend heavily on research and development, Fernandez said. That strategy will reveal itself over the next few years as results from drugs in development come in, he said. The only way to know if the strategy works is to wait for data, Fernandez said.

Research and development expenses this year will be $5 billion to $5.3 billion, Lilly said Thursday.

“2012 is an important year for Lilly, having entered the period when we face patent expirations on some of our largest products, most notably Zyprexa late last year and Cymbalta in the U.S. at the end of 2013,” said CEO John Lechleiter in the prepared statement. “We’ve been preparing to meet these challenges for many years, and have the plans in place to enable us to bridge this period and return to sustainable growth after 2014.”

Cymbalta, approved for the treatment of depression, anxiety disorder and fibromyalgia, generated sales of $3.5 billion in 2010, according to Bloomberg data.

The drugmaker has treatments for Alzheimer’s, diabetes and cancer in final-stage trials. As Lilly awaits these results, the company is focusing effort on growth areas such as emerging markets and animal health, Lechleiter said.

Lilly sees Zyprexa revenue plunging by over $3 billion in 2012. The drug rang up more than $5 billion in 2010 sales, the last full year before its U.S. patent expired. That happened in October, exposing Zyprexa to competition from cheaper generic versions of the drug.

Several big drugmakers are dealing with patent expirations on key products, but analysts say Lilly faces one of the biggest hits. In addition to Zyprexa, the company will lose protection for its second-best seller, the antidepressant Cymbalta, in 2013.

By 2014, the drugmaker will have lost U.S. patents protecting five drugs that generated 64 percent of Lilly's U.S. product sales in 2010. That includes the diabetes treatment Humalog and the cancer drug Gemzar, which has seen sales plummet since it lost patent protection in November 2010.

Analysts expect the company's earnings to drop through 2014 before rebounding, and some question how the company can replace that revenue and maintain its dividend at the current quarterly rate of 49 cents per share.

In October, Fitch Ratings downgraded several Lilly debt ratings on concerns about the patent expirations.

Lilly officials have said they have no plans to reduce the dividend. The company has been preparing for the revenue losses for years and is trying to offset them with cost-cutting, its pipeline of drugs under development, its animal health business, sales in emerging markets like China, and with sales growth in Japan.

Lilly said Thursday it now has a dozen potential drugs in late-stage clinical testing, the last phase before a company seeks regulatory approval to sell a drug. That beats its goal of 10 by the end of the year. 


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. If I were a developer I would be looking at the Fountain Square and Fletcher Place neighborhoods instead of Broad Ripple. I would avoid the dysfunctional BRVA with all of their headaches. It's like deciding between a Blackberry or an iPhone 5s smartphone. BR is greatly in need of updates. It has become stale and outdated. Whereas Fountain Square, Fletcher Place and Mass Ave have become the "new" Broad Ripples. Every time I see people on the strip in BR on the weekend I want to ask them, "How is it you are not familiar with Fountain Square or Mass Ave? You have choices and you choose BR?" Long vacant storefronts like the old Scholar's Inn Bake House and ZA, both on prominent corners, hurt the village's image. Many business on the strip could use updated facades. Cigarette butt covered sidewalks and graffiti covered walls don't help either. The whole strip just looks like it needs to be power washed. I know there is more to the BRV than the 700-1100 blocks of Broad Ripple Ave, but that is what people see when they think of BR. It will always be a nice place live, but is quickly becoming a not-so-nice place to visit.

  2. I sure hope so and would gladly join a law suit against them. They flat out rob people and their little punk scam artist telephone losers actually enjoy it. I would love to run into one of them some day!!

  3. Biggest scam ever!! Took 307 out of my bank ac count. Never received a single call! They prey on new small business and flat out rob them! Do not sign up with these thieves. I filed a complaint with the ftc. I suggest doing the same ic they robbed you too.

  4. Woohoo! We're #200!!! Absolutely disgusting. Bring on the congestion. Indianapolis NEEDS it.

  5. So Westfield invested about $30M in developing Grand Park and attendance to date is good enough that local hotel can't meet the demand. Carmel invested $180M in the Palladium - which generates zero hotel demand for its casino acts. Which Mayor made the better decision?